ישראל - עברית - Ministry of Health

inovamed ltd - magnesium sulfate as heptahydrate - תמיסה להזרקה\אינפוזיה - magnesium sulfate as heptahydrate 500 mg / 1 ml - magnesium sulfate

ישראל - עברית - Ministry of Health

a.l. medi-market ltd. - magnesium sulfate heptahydrate - תמיסה להזרקה\אינפוזיה - magnesium sulfate heptahydrate 500 mg / 1 ml - magnesium sulfate

ישראל - עברית - Ministry of Health

תעשיות תמרוקים שיק 1989 בעמ - צביעת ציפורניים

ישראל - עברית - Ministry of Health

לבנט טכנולוגיות בע"מ - רופא - מיועד לבדיקות קליניות ומחקר בתחום הנאורופיזיולוגיה , נאורולוגיה ופסיכיאטריה

ישראל - עברית - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - magnesium chloride 0.1017 g/l; sodium chloride 5.786 g/l; calcium chloride 0.2573 g/l; glucose as monohydrate 16.5 g/l; lactic acid as sodium 3.925 g/l - combinations of electrolytes - combinations of electrolytes - for patients with (decompensated) chronic renal failure being maintained on peritoneal dialysis.

ישראל - עברית - Ministry of Health

pharma shalom - aluminium oxide hydrated; dimethicone; magnesium hydroxide - טבליות לעיסות - magnesium hydroxide 200 mg; dimethicone 25 mg; aluminium oxide hydrated 200 mg - combinations

ישראל - עברית - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - magnesium chloride 0.1017 g; calcium chloride 0.1838 g; glucose as monohydrate 16.5 g; lactic acid as sodium 3.925 g; sodium chloride 5.786 g - combinations - combinations - for use in patients with end-stage (decompersated )chronic renal failure of any origin which can be treated with peritoneal dealysis.

ישראל - עברית - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - magnesium chloride 0.1017 g; glucose as monohydrate 25 g; calcium chloride 0.1838 g; sodium chloride 5.786 g; lactic acid as sodium 3.925 g - combinations - combinations - for use in patients with end-stage (decompersated )chronic renal failure of any origin which can be treated with peritoneal dealysis.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - atorvastatin as magnesium - טבליה - atorvastatin as magnesium 10 mg - atorvastatin - atorvastatin - atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains

ישראל - עברית - Ministry of Health

unipharm ltd, israel - atorvastatin as magnesium - טבליה - atorvastatin as magnesium 20 mg - atorvastatin - atorvastatin - atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains